Cargando…
Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma
Sodium iodide symporter (NIS) gene transfer for active accumulation of iodide in tumor cells is a powerful theranostic strategy facilitating both diagnostic and therapeutic application of radioiodide. In glioblastoma (GBM), the blood-brain barrier (BBB) presents an additional delivery barrier for nu...
Autores principales: | Spellerberg, Rebekka, Benli-Hoppe, Teoman, Kitzberger, Carolin, Hageneier, Mara, Schwenk, Nathalie, Öztürk, Özgür, Steiger, Katja, Multhoff, Gabriele, Eiber, Matthias, Schilling, Franz, Weber, Wolfgang A., Kälin, Roland E., Glass, Rainer, Nelson, Peter J., Wagner, Ernst, Spitzweg, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709165/ https://www.ncbi.nlm.nih.gov/pubmed/36458201 http://dx.doi.org/10.1016/j.omto.2022.10.013 |
Ejemplares similares
-
Selective sodium iodide symporter (NIS) genetherapy of glioblastoma mediatedby EGFR-targeted lipopolyplexes
por: Spellerberg, Rebekka, et al.
Publicado: (2021) -
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice
por: Kitzberger, Carolin, et al.
Publicado: (2023) -
The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy
por: Kitzberger, Carolin, et al.
Publicado: (2022) -
Taking Advantage of the TGFB1 Biology in Differentiated Thyroid Cancer to Stimulate Sodium Iodide Symporter (NIS)-Mediated Iodide Uptake in Engineered Mesenchymal Stem Cells
por: Han, Yang, et al.
Publicado: (2021) -
OR14-05 Taking Advantage Of The Interleukin-6-Biology In Differentiated Thyroid Cancer To Stimulate Sodium Iodide Symporter (NIS)-mediated Iodide Uptake In Engineered Mesenchymal Stem Cells
por: Florentine Koehler, Viktoria, et al.
Publicado: (2023)